Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (204)	12/7/1998 10:03:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 804

This was very conservative news. Even less details and relevant data than reported in abstract. Type of response for all pts: CL, PR, DS, DP, mortality rate? Time for respond to therapy and therapy duration? Time to disease progression and relapse rate? Life expectation compared with therapy result?... I understand that principal investigators prefer to release trials data at medical conference fist , to inform medical professionals and conference participants. Than in news release. What are this preliminary results for combination of the thalidomide with chemotherapy in treating plasma cell leukemia and fulminant MM? Maybe CELG will release additional, more details, data from thalidomide clinical trials presented at ASH, but I am not holding my breath. I am pretty convicted that data are good and it is matter of time when will be known to general public. Cheers. Miljenko